The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; GlaxoSmithKline; Histosonics; Incyte; Ipsen; QED Therapeutics; Rafael Pharmaceuticals; SERVIER
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
 
Kent A. Griffith
No Relationships to Disclose
 
Laura Williams Goff
Consulting or Advisory Role - AstraZeneca; Athenum Consulting; Boehringer Ingelheim; Cardinal Health; Exelixis; Genentech; Merck; QED Therapeutics; Relay Therapeutics
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); Basilea (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Thomas Enzler
Research Funding - Abbvie; Amgen; AstraZeneca; AstraZeneca; BioMed Valley Discoveries (Inst); CanBas; Exelixis; Exelixis; Five Prime Therapeutics; Hoosier Cancer Research Network; NeoImmuneTech; Taiho Oncology
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; BioMed Valley Discoveries; Seagen